![\"\"](\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight20Logo-2.png\")
<\/p>\n<\/p>\n
Involved pharmaceutical companies in the <\/span>Thrombotic Thrombocytopenic Purpura<\/strong> market are Takeda, Lee’s Pharmaceutical and others.<\/span><\/p>\n DelveInsight’s <\/span>Thrombotic Thrombocytopenic Purpura Pipeline Report<\/strong><\/a> provides a disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. This report gives a detailed clinical and non-clinical stage products analysis. The<\/span> TTP report<\/strong><\/a> also<\/span> highlights the unmet needs with respect to the development of Thrombotic Thrombocytopenic Purpura. <\/span><\/p>\n Some of the key highlights from the <\/strong>Thrombotic Thrombocytopenic Purpura Pipeline<\/strong><\/a> Report-<\/strong><\/p>\n Request for Sample<\/strong> @ <\/span>Thrombotic Thrombocytopenic Purpura Pipeline Insight<\/strong><\/a><\/p>\n Thrombotic Thrombocytopenic Purpura (TTP) is a rare, life-threatening thrombotic microangiopathy characterized by microangiopathic hemolytic anaemia, severe thrombocytopenia, and organ ischemia with profound thrombocytopenia. TTP is characterized by a severe deficiency in ADAMTS13 (a disintegrin & metalloprotease with thrombospondin type 1 repeats, member 13), the specific von Willebrand factor (vWf)-cleaving protease.<\/span><\/p>\n Thrombotic Thrombocytopenic Purpura Pipeline Emerging Therapies<\/strong><\/a>: Drug Profile<\/strong><\/p>\n BAX 930\/ TAK755\/SHP655 (Shire) is a fully glycosylated recombinant human ADAMTS-13 protein that restores the missing enzyme in a patient’s blood without the risk for complications for human-donor plasma. <\/span><\/p>\n The FDA has been granted <\/span>fast track designation <\/strong>to BAX930 for the therapy of acute episodes of hereditary TTP in patients with a constitutional deficiency of the von Willebrand factor-cleaving (VWF) protease ADAMTS13.<\/span><\/p>\n Currently, the drug is in phase III trial, which aims to assess the safety & efficacy of BAX 930 in the prevention & treatment of acute episodes of thrombotic thrombocytopenic purpura in participants with severe congenital deficiency of ADAMTS13.<\/span><\/p>\n Anfibatide (Lee’s Pharmaceutical) is a snake venom-derived protein that acts as a platelet glycoprotein Ib antagonist. It is in Phase II studies being evaluated as adjuvant therapy for plasma exchange in patients with acquired TTP. The drug has received an orphan designation for TTP from the US FDA.<\/span><\/p>\n Know More Information<\/strong> @ <\/span>Thrombotic Thrombocytopenic Purpura Pipeline Drugs<\/strong><\/a><\/p>\n Key Pipeline Therapies along with Companies <\/strong><\/p>\n![\"Thrombotic](\"http:\/\/beta-kiosk.icrowdnewswire.com\/assets\/source\/users\/delveinsight\/Thrombotic%20Thrombocytopenic%20Purpura%20Pipeline.png?1621401790157\")
<\/span><\/p>\n\n
\n
\n
\n